Gavreto Approved for Treatment of RET-Altered Thyroid Cancers



The FDA authorized pralsetinib (Gavreto, Genentech/Blueprint Medicines) for clients aged 12 years and older with innovative or metastatic RET-mutant medullary thyroid cancer who need systemic treatment or RET blend–favorable thyroid cancer who need systemic treatment and are radioactive iodine–refractory, if radioactive iodine is suitable.

Synesy.org